Fig. 3: DILA1 inhibits Cyclin D1 degradation via the ubiquitin–proteasome pathway.
From: LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
a, b Western blotting showing Cyclin D1 protein in MCF7-Pa (a) and MCF7-Re (b) cells treated with tamoxifen. c Western blotting showing Cyclin D1 protein in MCF7-Pa and MCF7-Re cells treated with CHX for the indicated time (left). The quantification of Cyclin D1 degradation rate by gray scale analysis (right). d Western blotting showing Cyclin D1 protein in MCF7-Pa and MCF7-Re cells treated with MG132 for the indicated time. e Western blotting showing Cyclin D1 protein in MCF7-Re cells transfected with NC or DILA-ASOs and then treated with MG132 for 24 h. f Western blotting showing Cyclin D1 protein in MCF7-Re cells transfected with NC or DILA-ASOs and then treated with CHX for the indicated time (left). The quantification of Cyclin D1 degradation rate by gray scale analysis (right). g Western blotting showing Cyclin D1 protein in MCF7-Pa cells transfected with control vector or vector expressing DILA1 and then treated with CHX (left). The quantification of Cyclin D1 degradation rate by gray scale analysis (right). h Ubiquitinated Cyclin D1 detected by immunoprecipitation with anti-Cyclin D1 antibody or IgG control and immunoblotting with anti-ubiquitin antibody in MCF7-Pa and MCF-Re cells. i Ubiquitinated Cyclin D1 detected by immunoprecipitation with anti-Cyclin D1 antibody or IgG control and immunoblotting with anti-ubiquitin antibody in MCF-Re cells transfected with NC or DILA-ASOs. For a–i, GAPDH was used as a loading control. Representative images of three biologically independent experiments are shown. For c, f, g, means ± s.d. are shown, and p values were determined by two-tailed Student’s test.
